Tiered Coagulation Monitoring Could Make Maternal Deaths From PPH Preventable
A new framework combining rapid point-of-care fibrinogen testing, viscoelastic assays, and lab tests could eliminate preventable postpartum deaths.
Summary
Postpartum hemorrhage is the leading cause of maternal death worldwide, and a key reason women die is that coagulation failure goes undetected until it is too late. Traditional blood clotting tests take too long for emergency obstetric care. This review proposes a tiered approach: rapid point-of-care fibrinogen measurement delivers results in under two minutes, viscoelastic testing (TEG/ROTEM) provides a dynamic picture of clot formation and breakdown, and standard laboratory assays ensure accuracy and consistency. Together, these tools allow clinicians to make faster, more precise transfusion decisions. The authors argue that combining all three modalities into a structured, data-driven protocol could transform postpartum hemorrhage management and potentially make maternal death from this cause fully preventable.
Detailed Summary
Postpartum hemorrhage (PPH) is the single most common cause of maternal mortality globally, yet many of these deaths are considered preventable with timely, targeted intervention. The central problem is not just uncontrolled bleeding but the rapid coagulopathy that follows — a secondary cascade of clotting factor depletion and dilution that outpaces conventional diagnostic timelines.
This review by Sumikura examines the evolving landscape of coagulation monitoring in obstetric emergencies. Traditional plasma-based assays — prothrombin time (PT), activated partial thromboplastin time (aPTT), and Clauss fibrinogen — have long been the diagnostic gold standard but carry a critical limitation: their turnaround time makes real-time decision-making impossible during acute hemorrhage.
Viscoelastic testing platforms, specifically TEG and ROTEM, represent a significant advancement by providing bedside visualization of the full clot lifecycle, from formation through fibrinolysis. This enables goal-directed transfusion therapy, reducing unnecessary blood product use and improving outcomes. However, these systems still require trained operators and several minutes to yield results.
The most compelling development highlighted is point-of-care (POC) fibrinogen measurement directly from whole blood, delivering quantitative results in approximately two minutes. Since fibrinogen is typically the first coagulation factor to reach critically low levels during major obstetric hemorrhage, its rapid measurement is arguably the most clinically urgent data point available.
The review proposes integrating all three modalities into a tiered framework: POC fibrinogen for immediate triage, viscoelastic testing for dynamic monitoring, and laboratory assays for standardization and confirmation. This multimodal strategy, paired with future digital decision-support tools, could systematically close the gap between hemorrhage onset and effective intervention. The authors suggest that structured coagulation monitoring, broadly implemented, may render maternal death from PPH entirely preventable — a bold but evidence-grounded claim.
Key Findings
- Point-of-care fibrinogen testing delivers whole-blood results in under 2 minutes, enabling immediate replacement decisions during PPH.
- Fibrinogen is the first coagulation factor to become critically depleted during major obstetric hemorrhage.
- TEG/ROTEM viscoelastic testing enables goal-directed transfusion, reducing unnecessary blood product use.
- A tiered three-modality framework — POC, viscoelastic, and lab testing — is proposed as the optimal PPH coagulation strategy.
- Digital decision-support systems integrated with real-time monitoring represent the next frontier in PPH management.
Methodology
This is a narrative review article authored by a single anesthesiologist and critical care specialist, synthesizing current evidence on coagulation monitoring modalities used in postpartum hemorrhage. No primary data collection, meta-analysis, or systematic search methodology is described. Conclusions are based on interpretation of existing literature and clinical reasoning.
Study Limitations
This summary is based on the abstract only, as the full text is not open access; detailed evidence synthesis, referenced studies, and nuanced arguments cannot be assessed. The paper is a single-author narrative review, which carries inherent risk of selection bias and lacks the rigor of a systematic review or meta-analysis. No new clinical data are presented, and the proposed tiered framework has not yet been validated in multicenter prospective trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.